Outcomes	MD_1	MD_2	MD_3	MD_4	MSP_1	MSP_2	MSP_3	MSP_4	Median	Notes: 1‐3 ‐‐> of limited importance 4‐6 ‐‐> important 7‐9 ‐‐> critical
Total number of SAEs	9	8	9	8	9	9	9	9	9.0	Critical
N° of participants free from EDSS worsening at 24 months	6	7	9	9	7	9	8	9	8.5	Critical
N° of participants with NEDA at 24 months	6	5	6	4	9	9	9	9	7.5	Critical
N° of participants who withdrew at the end of FU	7	7	9	8	8	5	1	9	7.5	Critical
Quality of life	9	9	6	7	9	7	7	7	7.0	Critical
N° of participants with cognitive impairment at 12 months	7	6	3	5	9	7	9	9	7.0	Critical
N° of participants with at least 1 AE at the end of FU	7	6	8	6	7	5	7	6	6.5	Important
N° of participants with at least 1 relapse over 12 months	7	6	6	5	4	8	8	6	6.0	Important
N° of participants with new gad T1 lesions or new/enlarging T2 MRI lesions	3	5	5	4	2	6	2	6	4.5	Important
N° of participants with brain atrophy at 24 months	Not rated	Not rated	Not rated	Not rated	Not rated	Not rated	Not rated	Not rated	Not rated	Of limited importance
MD: medical doctor; MSP: multiple sclerosis person; AEs: adverse events; EDSS: expanded disability status scale; FU: follow‐up; MRI: magnetic resonance imaging; NEDA: no evidence of disease activity; SAEs: serious adverse events